Pain Therapeutics, Inc. develops drugs for nervous system disorders in the United States. The company's lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone to treat severe chronic pain. It is also developing FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; PTI-125, a small molecule drug candidate to treat Alzheimer's disease; and PTI-125DX, a blood-based diagnostic/biomarker to detect Alzheimer's disease. The company was founded in 1998 and is based in Austin, Texas.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone512-501-2444
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees9
OptionableNot Optionable
Pain Therapeutics (NASDAQ:PTIE) Frequently Asked Questions
What is Pain Therapeutics' stock symbol?
Pain Therapeutics trades on the NASDAQ under the ticker symbol "PTIE."
When did Pain Therapeutics' stock split? How did Pain Therapeutics' stock split work?
Shares of Pain Therapeutics reverse split on Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 9th 2017. An investor that had 100 shares of Pain Therapeutics stock prior to the reverse split would have 14 shares after the split.
How were Pain Therapeutics' earnings last quarter?
Pain Therapeutics, Inc. (NASDAQ:PTIE) released its quarterly earnings data on Monday, October, 29th. The biopharmaceutical company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.61) by $0.50. View Pain Therapeutics' Earnings History.
When is Pain Therapeutics' next earnings date?
Has Pain Therapeutics been receiving favorable news coverage?
News articles about PTIE stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Pain Therapeutics earned a daily sentiment score of 0.9 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an effect on the stock's share price in the next several days.
Who are some of Pain Therapeutics' key competitors?
Some companies that are related to Pain Therapeutics include Provention Bio (PRVB), Entasis Therapeutics (ETTX), Alpine Immune Sciences (ALPN), Tetraphase Pharmaceuticals (TTPH), Medicure (MCUJF), Elite Pharmaceuticals (ELTP), Infinity Pharmaceuticals (INFI), CTI BioPharma (CTIC), Aridis Pharmaceuticals (ARDS), Fortress Biotech (FBIO), Synergy Pharmaceuticals (SGYP), KemPharm (KMPH), Zynerba Pharmaceuticals (ZYNE), Avenue Therapeutics (ATXI) and Scpharmaceuticals (SCPH).
Who are Pain Therapeutics' key executives?
Pain Therapeutics' management team includes the folowing people:
- Mr. Remi Barbier, Founder, Chairman, CEO & Pres (Age 59)
- Dr. Nadav Friedmann, COO, Chief Medical Officer & Director (Age 76)
- Mr. Eric J. Schoen, Chief Financial Officer (Age 51)
- Dr. Michael Marsman Pharm.D., Sr. VP of Regulatory Affairs
Who are Pain Therapeutics' major shareholders?
Pain Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Virtu Financial LLC (0.20%). Company insiders that own Pain Therapeutics stock include Armistice Capital Master Fund, Armistice Capital, Llc and Sanford Robertson. View Institutional Ownership Trends for Pain Therapeutics.
Which institutional investors are selling Pain Therapeutics stock?
PTIE stock was sold by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have sold Pain Therapeutics company stock in the last year include Armistice Capital Master Fund and Armistice Capital, Llc. View Insider Buying and Selling for Pain Therapeutics.
How do I buy shares of Pain Therapeutics?
Shares of PTIE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pain Therapeutics' stock price today?
One share of PTIE stock can currently be purchased for approximately $1.13.
How big of a company is Pain Therapeutics?
Pain Therapeutics has a market capitalization of $20.32 million. Pain Therapeutics employs 9 workers across the globe.
What is Pain Therapeutics' official website?
How can I contact Pain Therapeutics?
Pain Therapeutics' mailing address is 7801 NORTH CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The biopharmaceutical company can be reached via phone at 512-501-2444 or via email at [email protected]
MarketBeat Community Rating for Pain Therapeutics (NASDAQ PTIE)
MarketBeat's community ratings are surveys of what our community members think about Pain Therapeutics and other stocks. Vote "Outperform" if you believe PTIE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTIE will underperform the S&P 500 over the long term. You may vote once every thirty days.
